sunset_PARK
Posted - 2 days ago
$ITCI 12.13.24, 12600, +0%w/w, antipsychotics market -3%w/w, bipolar -3%w/w. Happy holidays, everyone!
Alonosley_45
Posted - 3 days ago
$ITCI $ROIV 🔥 MYNZ 🔥 NEWS: Mainz Biomed partners with Quest Diagnostics for a 15,000-patient FDA trial of ColoAlert, targeting U.S. colorectal cancer risk. Partnered w/ Quest (DGX) ($17.3B market cap, $9.25B revenue) for FDA study. Quest gets 18-mo U.S. marketing option for NextGen, distributing to physicians, hospitals, plans, employers & consumers. 🚀 Updated PT: $120 PT (+3,000%) - $440 PT (+12,000%) Recently, $8M to fast-track FDA, TMO co-developing mRNA-based CRC screening. Supporters: P. Starke, G. Starke, F. Muniz. Low float, $50 soon! 🔥
ThisIsBiotech
Posted - 4 days ago
$BMY $ABBV $ITCI $RVPH Having the “better drug” means nothing without clear, consistent data and market validation. KRTX and Cerevel pulled in multi-billion dollar deals because they delivered results that convinced investors and big pharma. If your drug really is superior, the market will reward it eventually, but for now, it sounds more like frustration than fact. Throwing shade at competitors doesn’t change the reality: success comes from proven data, strong execution, and clear differentiation. Until that’s in hand, the market isn’t going to “give you love” just because you think your drug is better. GL!
Toni19
Posted - 4 days ago
$BMY $ABBV $ITCI $RVPH So, when YOU are so smart, why KRTX and the other FAIL drug from ABBVIE/CEREVEL, get a bo for 14 billion and 8 billion dollar! We have the better drug, but for now, we get no love!! Until not! If that is only your answer bevor, better you are silence🤫
ThisIsBiotech
Posted - 4 days ago
$RVPH $ABBV $ITCI $BMY This seems like a bit of a stretch. While brilaroxazine may show promise, hyping it as a threat level molecul ignores the bigger picture. We’ve seen plenty of partial agonists come and go, with real-world issues like patient adherence, metabolic side effects, and CYP3A4 challenges limiting their success...
Also, dismissing competitors like Reviva and Neurocrine without full context seems premature. If this were such a game-changing molecule, it would already be clear in the data, not just speculative chatter. As for limited demographic data, this isn’t a new problem, and it’s unlikely one molecule solves it overnight. Better to stay grounded and watch for proven results before jumping ship.
Toni19
Posted - 4 days ago
$BMY $ABBV $ITCI $RVPH 👏👏👏 Smart observation and one of the BEST messages, for today!! 2025 will be a different game here!! Why? Because the drug Brilaroxazine works at BEST and is the BEST drug for Schizo!! You can thinking by your self, why just only 18 million dollar!! In 2025, you will see! Who was short, will closed the short position and go long!!
TBCLLC23
Posted - 4 days ago
@Toni19 @Itsybitsybeanbag we are just seeing the last of Hedgies shenanigans they need to unload their competitors shares at premium while they load up on $RVPH, would you still want to be holding $ABBV $ITCI or $BMY when brilaroxazine sees a 50pt drop in PANSS at one year with little side effects. This is a threat level molecule with this level of efficacy, they all misread Reviva against Cereval and Neurocrines failed new MOA molecules. Even though this is another partial agonist we know this MOA works , what hasn’t worked is the patient’s willingness to take and stay on the current medications due to side effects (mostly due to the CYP3A4 enzyme pathway used, eliminating efficacy within whole demographics such as the asian population, which this does not and has shown in the trial patients race, hence when you look at the current approved atypical clinical trials they all have limited asian population data)
megamaven
Posted - 5 days ago
$ITCI 14 shares traded. I'll take 1400 at that price
Fedtegreve
Posted - 5 days ago
$ITCI Heavy SP manipulation pre market. Only a few shares traded.
sunset_PARK
Posted - 1 week ago
$ITCI 12.06.24, 12600, +24%w/w, another new record. Antipsychotics market +20.6%, bipolar +20.1%.
Idvst8
Posted - 1 week ago
$ITCI Strong Close. Great company
Stellar_Capital
Posted - 1 week ago
$ITCI @sunset_PARK Insurance came though. Starting my first pill tonight.
heffer
Posted - 1 week ago
$ITCI $ITCI peculiar that CFO and president hold no shares. Any thoughts why? This has been for a cwhile.
sunset_PARK
Posted - 2 weeks ago
$ITCI for the 4-day week 11.29.24, 10200, -18% w/w, total antipsychotics market -16.1%, bipolar -15.4%
Idvst8
Posted - 2 weeks ago
$ITCI - Seems kind of cheap here again. Most of my BIO capital is tied up in Viking and Iovance, but ITCI is still one of the best GEMS. AXSM i think gets taken out in 2025, and ITCI should pop on the valuation metrics.
megamaven
Posted - 2 weeks ago
$ITCI boards quiet. Sometimes, this stock trades like it needs its own medicine. I'm happy to be here for the ride.
megamaven
Posted - 2 weeks ago
$ITCI gentle giant should be $125. Slow steps.
Best secret on wall street.
Jaydiggity
Posted - 2 weeks ago
$ITCI I know a LOT of pharma is down these days. I'm not a political guy so I won't comment on any administration policies but I will say that when it comes to ITCI, this is all NOISE that should be ignored. We just submitted our NDA application for Caplyta for depression. This is going to be HUGE for us! It typically takes around 10 months for the FDA to officially respond, right? And if the stock continues to fluctuate under $90 because of any other macro reasons, that is a gift for all of us to load up on shares! I'm listening to ITCI at the Evercore conference right now (you should, too!) and the very first question is about ITCI hitting profitability in 2025. Yet another reason to load up on shares! Good luck to longs.
briefingcom
Posted - 2 weeks ago
$ITCI: Intra-Cellular Therapies submits supplemental new drug application to FDA for CAPLYTA for the treatment of major depressive disorder as adjunctive therapy https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241203073322ITCI&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
Tangle22
Posted - 2 weeks ago
$EXEL $ITCI $ROIV @BraxtonSaunders what is MYNZ and what it has to do with EXEL? Your posting has no meaning stop adding exel in it.
heffer
Posted - 3 weeks ago
$ITCI I think M are has been signaling she wants to sell the company. Her mention of the company being worth $5 B is broadcasting what she is looking for.
Quantumup
Posted - 11/29/24
Mizuho reiterated $ITCI Outperform; $100. Mizuho says, We remain bullish on ITCI following its quarterly update last month, with 3Q characterized by (1) another revenue beat for Caplyta, (2) another 2024 revenue guidance raise, and (3) perhaps more importantly, first-time ever Caplyta peak sales guidance from management of at least $5bn within the next 10 years (note: we were already there). ITCI shares have responded well since this news (+13% vs. 1% for the XBI) and generally have outperformed this year (+21% YTD vs. +12% for the XBI). Bigger picture, we continue to view ITCI as a high-quality name that is executing flawlessly on Caplyta commercially, and with label expansion into major depressive disorder/MDD expected next year, we expect to see another significant inflection in Caplyta's sales trajectory. With an emerging pipeline that still represents 100% model upside, and the company, given its profile, also likely attracting strategic interest, we stay Outperform-rated on ITCI.
sunset_PARK
Posted - 11/29/24
$ITCI 11.22.24, 12300, +6% w/w, total antipsychotics market +4.2%w/w, bipolar +4.2%w/w. Not only a new record for caplyta but most competitors as well, Let me digress a bit. How common ppl take these drugs today!!Are they taking drugs like coffee and bear gummy?
CyclingGuy
Posted - 11/29/24
$ITCI Sharon expects 5 BILLION in annual Caplyta sales within a decade and she’s being conservative. https://finance.yahoo.com/news/intra-cellular-surprised-wall-street-110000332.html
Estimize
Posted - 11/28/24
Wall St is expecting -0.06 EPS for $ITCI Q4 [Reporting 02/26 BMO]
http://www.estimize.com/intro/itci?chart=historical&metric_name=eps&utm_c
vjtweet
Posted - 11/26/24
$ITCI opened a position today.
CaptainStonks
Posted - 11/25/24
$ITCI how’s everyone feeling on this one rn after all these new appointments?
juzaoftheclouds
Posted - 11/24/24
$ITCI I'm asking to whoever is willing to share his opinion. Wouldn't a superiority trial vs antidepressants alone in a population of antidepressants responders have been more significant, as opposed to superiority in a population of sub-responders?
MagicPills
Posted - 11/23/24
$AXSM $TGTX $ITCI $VKTX Leerink Biotech Late-Stage M&A Retrospective: Analyzing Time from Approval/Pivotal Data to Deal Our analysis suggests acquisitions typically happen within a year of the key de-risking event. Across this broad range of deals, the average was 10.6 months with a median of 4.9 months. If we exclude two outliers (Celgene-Abraxis 2010, and Pfizer [PFE, MP]-Medivation 2016), the average drops to 9.4 months. We think this is an interesting proxy for the time needed for prospective acquirers to identify the target, conduct due diligence, and undergo a negotiation process. Also note that acquirers are likely already evaluating target companies prior to the de-risking event (or post-data/pre-approval even when the deal gets done post-approval), so these metrics underestimate the true timeline....."
